

**UAP1 Antibody (C-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP17782b****Specification**

---

**UAP1 Antibody (C-term) Blocking Peptide - Product Information**Primary Accession [Q16222](#)**UAP1 Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 6675**Other Names**

UDP-N-acetylhexosamine pyrophosphorylase, Antigen X, AGX, Sperm-associated antigen 2, UDP-N-acetylgalactosamine pyrophosphorylase, AGX-1, UDP-N-acetylglucosamine pyrophosphorylase, AGX-2, UAP1, SPAG2

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**UAP1 Antibody (C-term) Blocking Peptide - Protein Information****Name** UAP1 {ECO:0000303|PubMed:9603950, ECO:0000312|HGNC:HGNC:12457}**Function**

Catalyzes the last step in biosynthesis of uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc) by converting UTP and glucosamine 1-phosphate (GlcNAc-1-P) to the sugar nucleotide (PubMed:<a href="http://www.uniprot.org/citations/9603950" target="\_blank">9603950</a>, PubMed:<a href="http://www.uniprot.org/citations/9765219" target="\_blank">9765219</a>). Also converts UTP and galactosamine 1-phosphate (GalNAc-1-P) into uridine diphosphate-N-acetylgalactosamine (UDP-GalNAc) (PubMed:<a href="http://www.uniprot.org/citations/9765219" target="\_blank">9765219</a>). In addition to its role in metabolism, acts as a regulator of innate immunity in response to virus infection by mediating pyrophosphorylation of IRF3: catalyzes pyrophosphorylation of IRF3 phosphorylated at 'Ser-386' by TBK1, promoting IRF3 dimerization and activation, leading to type I interferon responses (PubMed:<a href="http://www.uniprot.org/citations/36603579" target="\_blank">36603579</a>).

**Cellular Location**

Cytoplasm, cytosol. Note=In spermatozoa, localized to the principal piece of the tail, the neck region of the head and to a lesser extent, the midpiece of the tail.

**Tissue Location**

Widely expressed (PubMed:8025165). Expressed at low level in placenta, muscle and liver (PubMed:8025165) [Isoform AGX2]: Isoform AGX2 is more abundant than isoform AGX1 in somatic tissue.

**UAP1 Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**UAP1 Antibody (C-term) Blocking Peptide - Images****UAP1 Antibody (C-term) Blocking Peptide - Background**

UAP1 converts UDP and GlcNAc-1-P into UDP-GlcNAc, and UDP and GalNAc-1-P into UDP-GalNAc. Isoform AGX1 has 2 to 3 times higher activity towards GalNAc-1-P, while isoform AGX2 has 8 times more activity towards GlcNAc-1-P.

**UAP1 Antibody (C-term) Blocking Peptide - References**

Ehret, G.B., et al. Eur. J. Hum. Genet. 17(12):1650-1657(2009)Wang, A.G., et al. Biochem. Biophys. Res. Commun. 345(3):1022-1032(2006)Peneff, C., et al. EMBO J. 20(22):6191-6202(2001)Wang-Gillam, A., et al. J. Biol. Chem. 273(42):27055-27057(1998)Diekman, A.B., et al. Mol. Reprod. Dev. 50(3):284-293(1998)